Cargando…
Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia
Autores principales: | Xu, Bojun, Liu, Suying, Li, Yan, Zhao, Liangbin, Song, Xinyao, Chen, Tong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573001/ https://www.ncbi.nlm.nih.gov/pubmed/34754441 http://dx.doi.org/10.1093/ckj/sfab134 |
Ejemplares similares
-
Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
por: Wu, Yunzhou, et al.
Publicado: (2020) -
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients
por: Rahbar, Maryam, et al.
Publicado: (2017) -
Ten year follow up of erythropoietin induced autoimmune pure red cell aplasia
por: Ram, R., et al.
Publicado: (2013) -
Erythropoietin‐induced pure red cell aplasia
por: Yeung, Vivian K. P.
Publicado: (2022) -
Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin
por: Padhi, Somanath, et al.
Publicado: (2021)